Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-response study of netupitant in patients receiving highly emetogenic chemotherapy
jRCT2080222433Phase 2
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of netupitant in chemotherapy-induced nausea and vomiting (CINV) (3 arms), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
netupitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCT2080222433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222433.